Pregled bibliografske jedinice broj: 141319
Interleukin-6 and its receptors in the CSF and serum of relapsing-remitting multiple sclerosis patients
Interleukin-6 and its receptors in the CSF and serum of relapsing-remitting multiple sclerosis patients // Abstract book
Brijuni, Hrvatska, 2003. (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 141319 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Interleukin-6 and its receptors in the CSF and serum of relapsing-remitting multiple sclerosis patients
Autori
Horvat, Gordana ; Čulo, Filip ; Lukinović-Škudar, Vesna
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstract book
/ - , 2003
Skup
Annual Meeting of the Croatian Immunological Society
Mjesto i datum
Brijuni, Hrvatska, 17.10.2003. - 19.10.2003
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
Il-6; gp130; sIL-6R; multiple sclerosis
Sažetak
Introduction: Inteleukin-6 (IL-6) is pleiotropic cytokine that influence antigen specific immune responses and inflammatory reactions. The functional receptor for IL-6 is a complex of signal transducing subunit glycoprotein 130 (sgp130) and the ligand binding subunit gp80 (sIL-6R). They interact to mediate intracellular signalling. Expression of IL-6 in multiple sclerosis (MS) is controversial and no convincing correlations have yet been made between IL-6 levels and disease activity The aim of this study was to measure IL-6 and its receptors in the cerebrospinal fluid (CSF) and serum from relapsing-remitting MS (RRMS) patients during acute exacerbation of the disease. Patients and methods: We analysed cerebrospinal fluid (CSF) and serum samples of 36 relapsing-remitting MS (RRMS) patients diagnosed according to the McDonald criteria during acute exacerbation of the disease, and 41 patients with noninflammatory neurological diseases (NIND), as controls. IL-6, sIL-6R and sgp130 levels were measured using commercial enzymeimmuno assay (ELISA). Student-t test was applied for statistical analysis of the data. Results: The results were expressed as mean ± ; S.D. in pg/mL. Our results showed no statistical difference between all of the tested groups (p>0.05) and were as follows. Serum IL-6 level in RRMS was 18.06 ± ; 47.58 and in NIND was 38.00 ± ; 79.65. CSF IL-6 level in RRMS was 2.74 ± ; 2.41 and in NIND group it was 2.26 ± ; 2.37. Serum sIL-6R level was in RRMS 24845.33 ± ; 11117.87 and in NIND was 22739.16 ± ; 10098.05. CSF level of sIL-6R was in RRMS 528.99 ± ; 467.95 and in NIND it was 484.51 ± ; 789.43. Serum sgp130 levels were in RRMS group 710950 ± ; 82950 and in NIND 801970 ± ; 128911. The CSF sgp130 level was in RRMS 30470 ± ; 29750 and in NIND was 38450 ± ; 27210. Conclusion: Our results suggest that IL-6 and its soluble receptors (sIL-6R and sgp130) are probably not altered in RRMS during acute exacerbation of the disease.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti